Wall Street Zen lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a hold rating in a research note released on Saturday morning. Citigroup restated a “market perform” rating on shares of Incyte in a research report on Wednesday, July 15th. Morgan Stanley set a $119.00 target price on Incyte in a research report on Wednesday, July 29th. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 124 shares during the period. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.